Clinical trials: Metastatic Nasopharyngeal Cancer
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of sintilimab combined with anlotinib and taxane-based chemotherapy in patients with recurrent (not unable to locally curative treatment) or…
- Trial name
- NCT07581821
- Testing
- Sintilimab + Anlotinib + taxane-based chemotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Ming-Yuan Chen
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002507
- Testing
- mitomycin C, porfiromycin, brachytherapy
- Where
- United States
- Sponsor
- Yale University
Head and Neck Cancer
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898742
- Testing
- DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or…
- Trial name
- NCT00281866
- Testing
- erlotinib hydrochloride
- Where
- 2 sites in United States, Spain
- Volunteers
- 37 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant…
- Conditions
- Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin
- Trial name
- NCT03422536
- Testing
- Cetuximab, Ficlatuzumab
- Where
- 6 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Arizona
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma by AJCC V8 Stage
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
A Randomized, Double-Blind, Multi-Center Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) + Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized…
- Trial name
- NCT05513573
- Testing
- HLX07, HLX10, chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Henlius Biotech
Nasopharyngeal Carcinoma
Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV).
- Trial name
- NCT03830996
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Non Small Cell Lung Cancer, Nasopharyngeal Cancer
Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
Contrast enhancement ultrasonography（CEUS）could be used to evaluate the blood flow perfusion liver cancer. In this clinical trial, CEUS was used to evaluated the changes of blood flow perfusion of Secondary Malignant Neoplasm of…
- Conditions
- Non Small Cell Lung Cancer, Nasopharyngeal Cancer, Liver Metastasis
- Trial name
- NCT01347424
- Testing
- Paclitaxel , carboplatin, endostatin, Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003582
- Testing
- amifostine trihydrate, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Miami
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Nasopharyngeal Carcinoma, Metastasis
SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma
Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.
- Conditions
- Nasopharyngeal Carcinoma, Metastasis, Stereotactic Body Radiation Therapy
- Trial name
- NCT04351282
- Testing
- SBRT
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Recurrent or Metastatic Nasopharyngeal Carcinoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative…
- Trial name
- NCT06472713
- Testing
- Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Ming-Yuan Chen
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with…
- Trial name
- NCT07258979
- Testing
- YL201, Toripalimab, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 202 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Hepatic Artery Infusion Pump for NPC Liver Metastases
A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver.
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Liver
- Trial name
- NCT03876574
- Testing
- DSA-guided implantation of hepatic artery infusion pump, Gemcitabine, Floxuridine
- Volunteers
- 16 people
- Sponsor
- Xiangya Hospital of Central South University
Nasopharyngeal Carcinoma
Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma
The standard of care for locally advanced nasopharyngeal carcinoma is radical chemoradiation(CRT).Recent advances in radiation techniques and supportive measures resulted in improvemnent of locoregional control and quality of…
- Trial name
- NCT04898374
- Testing
- Gemcitabin/cisplatin
- Where
- Kuwait
- Volunteers
- 120 people
- Sponsor
- Kuwait Cancer Control Center